Abbott is teaming up with AtaCor Medical to develop a next-generation implantable cardioverter defibrillator (ICD) designed ...
One of the timeliest and, some say controversial, topics in clinical cardiac electrophysiology today is the proper role of the implantable cardioverter-defibrillator (ICD) in the treatment of patients ...
Background: Although more than 150,000 implantable cardioverter defibrillators (ICDs) are implanted yearly worldwide, only few studies systematically examined complications of ICD therapy in large ...
San Clemente-based cardiac device company AtaCor Medical announced a collaboration with Abbott Laboratories to develop a next ...
Cardiac device therapy has significantly evolved since the introduction of the first implantable pacemaker and the subsequent development of the implantable cardioverter-defibrillator (ICD). ICDs are ...
The indications for ICD implantation continue to expand; however, these devices are associated with complications related to the implantation procedure itself and morbidity caused by the normal and ...
First-of-its-kind Aurora EV-ICD™ system offers single device, single procedure with lead placed outside of heart and veins FDA approval of the Medtronic Aurora EV-ICD system includes the system's ...
Medtronic has received U.S. regulatory approval to sell a new implantable defibrillator that can be placed outside of the heart and veins to treat SCA — sudden cardiac arrest — an electrical problem ...
Please provide your email address to receive an email when new articles are posted on . Abbott announced that a cardiac resynchronization therapy defibrillator and an implantable cardioverter ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human extravascular implantable cardioverter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results